Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
CatalYm GmbH
The Canadian College of Naturopathic Medicine
Brigham and Women's Hospital
Massachusetts General Hospital
CatalYm GmbH
Hope Biosciences Research Foundation
National Cancer Institute (NCI)
University of Florida
MitoImmune Therapeutics
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Aston Sci. Inc.
University of Chicago
Chang Gung Memorial Hospital
National Cancer Center, Korea
Seoul National University Hospital
CSL Behring
Children's National Research Institute
Ottawa Hospital Research Institute
Wuhan University
Massachusetts Eye and Ear Infirmary
Sun Yat-sen University
Innate Pharma
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Merck Sharp & Dohme LLC
Milton S. Hershey Medical Center
Fundação Educacional Serra dos Órgãos
Midwestern Regional Medical Center
Morphotek
Indiana University
Tianjin Medical University Cancer Institute and Hospital
Bristol-Myers Squibb
Bristol-Myers Squibb
Zhejiang University
Duke University
European Society for Blood and Marrow Transplantation
Korea Research Foundation
Windy Hill Medical, Inc.